BCR-ABL is a dubious disease in the field of blood tumors, with complex clinical outcomes and often involving multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological biopsies.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of BCR-ABL-negative chronic myelogenous leukemia require individualized treatment regimens, typically including pharmacotherapy, rehabilitation interventions, regular follow-up, and multi-dimensional management. In recent years, significant improvements have been made to many previously difficult-to-treat blood tumour diseases with treatment-oriented treatment, immune-regulatory therapy, and precision medicine.
Treatment requires close monitoring of therapeutic efficacy and adverse reactions and timely adjustment of regimens according to changing conditions. Multidisciplinary collaboration MDT is particularly important for the overall management of BCR-ABL-negative non-chronic myelogenous leukemia. The platform serves the China International Medical Service System, which combines a team of authoritative experts at home and abroad in the field of blood oncology to provide the following services to patients: 1.
Remote pre-diagnosis: pre-examination of medical history, precise diagnostic directions and medical advice by a team of experts; 2. Interviews in China: arranging face-to-face diagnosis with authoritative experts, developing personalized treatment programs; 3. Full-service: one-stop services: providing medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects. Support for remote pre-diagnosis, visiting interviews, full translation and escort.